Clin2
NCT07458061Possibly a fitRecruiting

Kamuvudine-9 for diabetic macular edema

Diabetic Macular Edema

Part of Eyes & vision, Hormones & metabolism clinical trials.

This trial tests a new drug, Kamuvudine-9 (K9), to treat diabetic macular edema (swelling in the back of the eye caused by diabetes). It may help improve vision in people with diabetes who have not yet needed major treatments.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
10 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have diabetes (type 1 or 2) and diabetic macular edema (DME) confirmed by your doctor.
  • Your vision in the study eye is between 20/50 and 20/320 (moderate to severe vision loss).
  • You have not had certain recent eye treatments (like anti-VEGF injections or steroids) or eye surgery.
  • You are not pregnant, breastfeeding, or planning to become pregnant during the study.
  • You weigh at least 55 kg (about 121 pounds).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07459829Not yet recruiting· Phase 2
Study of an experimental drug for diabetic macular edema

This trial tests an investigational drug called CU06-1004 for people with diabetic macular edema (swelling in the center of the retina caused by diabetes). It aims to see if the drug can improve vision and reduce swelling.

NCT06305416Recruiting· Phase 3
Ranibizumab for diabetic macular edema

This trial tests an injection called Ranibizumab (10 mg/ml) to treat diabetic macular edema, a condition where fluid builds up in the center of the retina and causes blurry vision. The goal is to see if the drug is safe and effective at improving vision.

Dhaka
NCT07553429Recruiting· Phase 1/Phase 2
Testing a new eye injection for diabetic swelling

This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.

Phoenix, Arizona
NCT07199777Not yet recruiting· Phase 2
Study of SNP318 for diabetic macular edema

This trial tests an investigational drug called SNP318 for people with diabetic macular edema (DME). The goal is to see if it is safe and can improve vision.

NCT04187443Recruiting· Phase 1
Drug MS-553 for diabetic eye swelling with reduced vision

This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.

Changsha, Hunan
NCT06845163Recruiting· Phase 2
Testing dapagliflozin for diabetic macular edema

This study tests whether a medication called dapagliflozin, which is usually used for diabetes and heart failure, can help reduce swelling in the retina (diabetic macular edema) and improve vision. It is for people with type 2 diabetes who are already taking insulin and metformin.

Alexandria, Alexandria Governorate

Hear when a new Diabetic Macular Edema trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.